|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||56.56 - 57.82|
|52 Week Range||56.09 - 77.79|
|PE Ratio (TTM)||10.78|
|Earnings Date||Apr 26, 2018|
|Forward Dividend & Yield||2.80 (4.42%)|
|1y Target Est||77.07|
Some analysts say that a shift toward vaping among pot users could make the marijuana business an opportunity for big tobacco firms like Altria Group and Turning Point Brands.
Philip Morris International Inc. (NYSE:PM) shares fell off a cliff on April 19 after the company reported disappointing earnings. The fall was bigger than the disappointment, but it seemed to portend trouble for tobacco generally and took the whole consumer staples sector of the market down with it. The company — which sells exclusively outside the U.S. and spun-out from Altria Group Inc (NYSE:MO) in 2008 — had net income of $1.65 billion, $1.00 per share, on revenue of $6.9 billion.
Weak shipment volumes stemming from declining cigarette sales have long been a hurdle for firms in the tobacco space. However, RRPs are likely to continue expanding.
Zacks Investment Ideas feature highlights: Phillip Morris International, Altria and British American Tobacco
NEW YORK, NY / ACCESSWIRE / April 20, 2018 / It was a depressing day for tobacco stocks Philip Morris and Altria on Thursday. Philip Morris delivered lackluster results for the first quarter and Altria ...
To cement the concept in your pretty little heads, just take a look at the Bloomberg Commodity Index over the past year, as dollar valuations have declined. Does not anyone else feel that increasing short-term rates on schedule while drawing liquidity from the economy on an incrementally increasing basis is the least bit dangerous?
After its stock fell the most in a decade on Thursday, Philip Morris International Inc.’s challenge is to convince baby boomers to switch from cigarette smoking to a distinctly millennial activity -- fiddling ...
Philip Morris International is struggling to persuade people to stop smoking cigarettes. In Japan, the over-50s are still setting fire to cancer-causing sticks like there is no tomorrow. Its shares fell as much as 18 per cent, their worst decline since it split from Altria in 2008.
Wall Street's three major indexes closed lower on Thursday, with tobacco stocks leading a tumble in consumer staples while concerns about smartphone demand hurt the technology sector and rising bond yields and earnings helped financials rebound. The market pared some losses late in the session after Bloomberg reported that Deputy Attorney General Rod Rosenstein told President Donald Trump last week he is not a target of Special Counsel Robert Mueller’s Russia investigation.
Weak revenue growth from Philip Morris and concerns about its vape product sent both tobacco stocks lower.
Philip Morris International said growth of iQOS, its heat-not-burn tobacco product, slowed in Japan. Altria and British American Tobacco shares also slid. Philip Morris International PM shares plummeted 17 percent, on track for the company's worst day since it spun off from Altria in 2008, after PMI posted mixed first-quarter results and said growth of iQOS, its heat-not-burn tobacco product, slowed in Japan.
As of April 17, 2018, Altria Group (MO) was trading at $63.97. On March 26, 2018, Deutsche Bank initiated coverage of Altria with a “buy” rating and a target price of $72. Steve Powers of Deutsche Bank pointed out that Altria is trading at an attractive valuation multiple due to the recent decline in its stock.
For our analysis, we’ve used a forward PE (price-to-earnings) multiple due to the high visibility of Altria Group’s (MO) earnings. A forward PE multiple is calculated by dividing the company’s stock price from analysts’ earnings estimate for the next four quarters. The two announcements from the FDA that it’s considering policies to restrict the use of flavors in tobacco products and focusing on developing a comprehensive policy to lower nicotine levels in cigarettes led to declines in Altria stock and valuation multiple.
Analysts are expecting Altria Group (MO) to post adjusted EPS (earnings per share) of $0.92 in 1Q18, which represents a growth of 26% from $0.73 in 1Q17. Growth is expected to be driven by the expansion of Altria’s net margin, share repurchases, and marginal growth in revenue. Analysts are expecting Altria’s net margin to be 37.4% compared to 30.7% in 1Q17.
Analysts are expecting Altria Group (MO) to post revenue of $4.63 billion, which represents a growth of 0.9% from $4.59 billion in 1Q17. Revenue growth is expected to be driven by a rise in product prices. To drive its sales, Altria is focusing on the development of innovative products, packaging innovations, enhanced trade programs, and various marketing and promotional initiatives.
Altria Group (MO) is scheduled to announce its 1Q18 earnings before the market opens on April 26, 2018. As of April 17, 2018, Altria was trading at $63.97, which represents a fall of 9.1% since the announcement of its 4Q17 earnings on February 1, 2018.
NYU Langone Medical Center Professor Dr. Marc Siegel on the decline in opioid prescriptions filled this year and a report on the decline in smoking.